# Harbour BioMed Appoints Ms. Vivian Feng as Head of External Collaboration

- Link: https://www.thailand-business-news.com/pr-news/harbour-biomed-appoints-ms-vivian-feng-as-head-of-external-collaboration
- Published: 2026-11-05T13:57:00+07:00
- Author: PR Newswire

|   |

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 5, 2026 /PRNewswire/—
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company 
committed to the discovery and development of novel antibody therapeutics in immunology,
oncology and other areas, today announced the appointment of Ms. Vivian Feng as 
Senior Vice President, Head of External Collaboration. Ms. Feng will be based in
Shanghai and report directly to Mike Patten, Chief Strategy Officer of Harbour BioMed.

In this role, Ms. Feng will be responsible for leading and shaping Harbour BioMed’s
external collaboration strategy, connecting the Company’s platform, pipeline, and
innovation capabilities with partners to drive long-term corporate growth and value
creation. She will oversee business development and licensing activities across 
the HBM Group, foster synergy and information flow across its entities and NewCos,
and build the processes and team capabilities required for a scalable, risk-controlled
external collaboration function.

Ms. Feng brings over 16 years of end-to-end biotech and pharma business development
experience, spanning global licensing in and out, M&A, and equity investment. Most
recently, she served as General Manager of the Business Development Department at
Fosun Pharma, where she led global business development initiatives and established
a comprehensive group-level BD system covering valuation, due diligence, and risk
control.

Prior to Fosun Pharma, Ms. Feng held business development leadership roles at Besins
Healthcare Shanghai Limited, Shanghai Tenry Pharmaceutical Group, and Shanghai Newsummit
Pharmaceutical Group, where she successfully executed international out-licensing,
co-development projects, and over 100 product/asset evaluations.

Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed, commented: "We 
are very pleased to welcome Ms. Vivian Feng to Harbour BioMed. Vivian’s extensive
expertise in global licensing, corporate development, and strategic partnership 
management will be instrumental as we continue to advance our innovative pipeline
and expand our global partnerships. We look forward to working closely with her 
as we accelerate our growth and deliver on our mission to bring transformative therapies
to patients worldwide."

Ms. Vivian Feng, Senior Vice President, Head of External Collaboration of Harbour
BioMed, added: "I am thrilled to join Harbour BioMed at such a pivotal stage in 
the Company’s growth. Harbour BioMed’s innovative technology platform and highly
differentiated pipeline present tremendous opportunities for global collaboration.
I look forward to working with the team to build a world-class external collaboration
function that connects our platform and science with the right partners and brings
innovative therapies to patients globally."

Ms. Feng holds a Master of Science in Pharmaceutical Engineering from East China
University of Science and Technology.

**About Harbour BioMed**

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to 
the discovery and development of novel antibody therapeutics in immunology, oncology
and other areas. The Company is building a robust portfolio and differentiated pipeline
through internal R&D capability, strategic global collaborations in co-discovery
and co-development, and selective acquisitions.

Our proprietary antibody technology platform, Harbour Mice^(®), generates fully 
human monoclonal antibodies in both the conventional two heavy and two light chain(
H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies,
the HCAb-based immune cell engagers (HBICE^(®)) bispecific antibody technology enables
tumor-killing effects that traditional combination therapies cannot achieve. The
HCAb-based Antibody Plus technology (HCAb PLUS™) provides comprehensive modality
solutions for the development of innovative multi-specific medicines in different
disease areas. Additionally, building upon the Harbour Mice^(®) platform, Harbour
BioMed launched its first fully human Generative AI HCAb Model powered by its Hu-
mAtrIx™ AI platform, accelerating the development of innovative therapies.

By integrating Harbour Mice^(®), HBICE^(®), HCAb PLUS™, a single B-cell cloning 
platform and AI technologies, Harbour BioMed has built a highly efficient and distinctive
antibody discovery engine for developing next-generation therapeutic antibodies.
For more information, please visit [www.harbourbiomed.com](http://www.harbourbiomed.com/).

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Harbour BioMed Appoints Ms. Vivian Feng as Head of External Collaboration ](https://www.prnasia.com/story/archive/5089968_CN89968_0?rand=184833)